Multivitamin capsules and tablets refers to multivitamin drugs that are used to treat or prevent vitamin deficiencies brought on by a poor diet, specific diseases, or pregnancy. Vitamins are crucial for maintaining your health because they serve as the body's building blocks. Multivitamins tablets and capsules are a combination of many different vitamins that are normally found in foods and other natural sources The main types of products include multivitamins tablets and multivitamins capsules. A multivitamin is a pill that people take every day which contains a variety of vitamins and minerals. The different distribution channels include store-based, non-store-based and are used for energy and weight management, general health, bone, and joint health, gastrointestinal health, immunity, cardiac health, diabetes, anti-cancer, and other applications. These capsules and tablets are mainly used by adults, the geriatric population, pregnant women, children, and infants. The multivitamin capsules and tablets market research report is one of a series of new reports from The Business Research Company that provides multivitamin capsules and tablets market statistics, including multivitamin capsules and tablets industry global market size, regional shares, competitors with a multivitamin capsules and tablets market share, detailed multivitamin capsules and tablets market segments, market trends and opportunities, and any further data you may need to thrive in the multivitamin capsules and tablets industry. This multivitamin capsules and tablets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global multivitamin capsules and tablets market size grew from $20.28 billion in 2022 to $22.38 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The multivitamin capsules and tablets market size is expected to grow to $33.05 billion in 2027 at a CAGR of 10.2%. Increasing health consciousness among individuals is driving the market for multivitamin capsules and tablets. Multivitamins tablets or capsules are often prescribed by doctors to treat or prevent vitamin deficiency due to poor diet, certain illnesses, or during pregnancy as it contains different vitamins that are normally found in foods and other natural sources. The demand for multivitamins also increased attributing to rising health concerns associated with the COVID-19 pandemic. According to SVC Labs Ltd., a UK-based supplement manufacturer the sales for vitamins, minerals and supplements have increased since the beginning of March 2020 as people are concerned with boosting immune health. The sales of vitamins, minerals, and supplements have experienced growth of approximately 20%-140% since March 2020. Therefore, rising health consciousness is expected to drive the multivitamin capsules and tablets market during the forecast period. Shifting consumer focus towards flavored gummy vitamins for all ages is shaping the multivitamin capsules and tablets market. Consumers are searching for more convenient and entertaining supplement experiences, which will lead to a move toward flavored gummy vitamins. For instance, in April 2021, Persona Nutrition, a US-based company that provides personalized daily supplement packs launched daily gummy vitamin packs for the entire family. These daily packs are designed to help users achieve specific health goals, such as immune health, focus, relaxation, everyday support, and hair, skin, and nail health. This family pack includes multivitamins to boost muscle and nerve function. In February 2021, Nature's Way Products, a US-based wellness product manufacturing company, acquired Baze Labs for an undisclosed amount. Through this acquisition, Nature's Way increases its personalized nutrition product capabilities for its customers, home blood test services, and monthly subscription programs. Baze Labs is a US-based personalized nutrition manufacturing company specializing in the development of vitamins and supplements. Major players in the multivitamin capsules and tablets market are Herbalife Nutrition, Abbott Laboratories, Bayer, Nature's Bounty Co., Bionova Lifesciences, Ayanda GmbH, NutraMarks Inc., American Health Inc., Otsuka Holdings Co. Ltd., Nature's Way Products, Glanbia PLC., Pfizer, Mylan N.V., and Dymatize. Asia-Pacific was the largest region in the multivitamin capsules and tablets market in 2022. North America was the second-largest market in the multivitamin capsules and tablets market. The regions covered in multivitamin capsules and tablets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the multivitamin capsules and tablets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The multivitamin capsules and tablets market consists of sales of antioxidant capsule, iron folic acid tablet, multivitamin gummy, and nicotinamide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global multivitamin capsules and tablets market is segmented - 1) By Type: Multivitamins Tablets, Multivitamins Capsules 2) By Distribution Channel: Store Based, Non-Store Based 3) By Application: Energy & Weight Management, General Health, Bone & Joint Health, Gastrointestinal Health, Immunity, Cardiac Health, Diabetes, Anti-Cancer, Other Applications 4) By End User: Adults, Geriatric, Pregnant Women, Children, Infants

A tablet is a small portable computer that accepts input directly on the screen rather than a keyboard or mouse. The main types of tablets are detachable, slate, hybrid and rugged. A detachable tablet are entirely free of its keyboard and are small and lightweight. Tablets mainly have iOS android and windows operating systems and comes in below 8', 8' and above 8' sizes. Tablets are used for personal and business applications. The tablets market research report is one of a series of new reports from The Business Research Company that provides tablets market statistics, including tablets industry global market size, regional shares, competitors with a tablets market share, detailed tablets market segments, market trends and opportunities, and any further data you may need to thrive in the tablets industry. This tablets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global tablets market size will grow from $84.12 billion in 2022 to $94.96 billion in 2023 at a compound annual growth rate (CAGR) of 12.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global tablets market size is expected to grow to $147.38 billion in 2027 at a CAGR of 11.6%. The increasing demand for tablets in various sectors such as healthcare, education, entertainment and other industries is a key factor driving the growth of the tablets market. For instance, the hospitality industry has introduced in-room tablets to offer their services at the fingertips of their guests. Similarly, tablets help the transportation industry to standardize workflows, facilitate proper communications on time and provide critical information. The increasing use of tablets across industries is driving sales. In 2020, the sales of the Apple iPad increased by 20%, delivering more than 14 million units and Samsung stood in second place, delivering 7 million units and growing by 39%. The increasing demand for tablets in different sectors is expected to fuel the market for tablets. Major companies operating in the tablets market are focusing on developing innovative technology solutions for tablets. For instance, in June 2020, Apple a USA based technology company launched Apple iPad Pro 11 2020. The iPad Pro is fitted with an Apple A12Z Bionic octa-core processor, based on iPadOS and powered by a non-removable Li-Po battery (28.65 Wh). The tablet's sensors include a proximity sensor, barometer, accelerometer, gyroscope and sensor for ambient light, liquid retina display. Therefore, making the tablets technologically advanced helps companies to sustain the competitive market. Major players in the tablets market are Apple Inc., AsusTek Computer Inc., Samsung Electronics Co. Ltd., Lenovo Group Ltd., Acer Inc., Microsoft Corporation, HP, Huawei, LG Electronics Inc., Archos, Chuwi Innovation Limited, Dell, HTC Corporation, Lava International Limited, Nokia Corporation, Panasonic Corporation, Sony Corporation and Toshiba Corporation. The Asia-Pacific was the largest region in the tablets market in 2022. North America is expected to be the fastest-growing region in the global tablets market report during the forecast period. The regions covered in the global tablets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the tablets market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The tablets market consists of sales of tablets which are portable computers that use touchscreens as their primary input. Most tablets are slightly smaller and weigh less than an average laptop. Generally, the size of a tablet screen is smaller than a laptop computer and larger than a smartphone. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global tablets market is segmented - 1) By Product Type: Detachable, Slate, Hybrid, Rugged 2) By Application: Personal, Business 3) By Operating Systems: iOS, Android, Windows 4) By Screen Size: below 8", 8", Above 8"

Drug delivery devices are used to deliver specific drugs to a specific part of the body to cure diseases. Drug delivery devices used in various patient care settings, such as hospitals, diagnostic centers, clinics, and home care settings, are included in this market. The main routes of administration of drug delivery devices is oral drug delivery, injectable drug delivery, topical drug delivery, ocular drug delivery, pulmonary drug delivery, nasal drug delivery, transmucosal drug delivery, and implantable drug delivery. Oral drug delivery is a route of drug delivery in which a tablet or capsule is administered into the alimentary canal of a human being. The patient care settings is hospitals, diagnostic centres, ambulatory surgery centres/clinics, home care settings, and others. The various applications involved are cancer, infectious diseases, respiratory diseases, diabetes, cardiovascular diseases, autoimmune diseases, central nervous system disorders, and others. The drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides drug delivery devices market statistics, including drug delivery devices industry global market size, regional shares, competitors with a drug delivery devices market share, detailed drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the drug delivery devices industry. This drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global drug delivery devices market size will grow from $81.13 billion in 2022 to $87.65 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drug delivery devices market size is expected to grow from $115.09 billion in 2027 at a CAGR of 7.0%. The rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer and other diseases is expected to drive the drug delivery devices market. According to the world health organization (WHO), by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and 71% of deaths due to ischemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. There are various routes of drug administration for medical drugs. The selection of the route depends on three factors - the effect desired; the type of the disease and the type of the product. Currently, the development of new drug delivery systems plays a major role in the pharmaceutical industry. Research and development (R&D) in drug delivery are increasing throughout the world due to the increasing prevalence of these diseases. Most pharmaceutical companies are focusing on multiple drug delivery technologies for creating excellent advantages and better outcomes for their marketed products. Hence, the increasing prevalence of chronic diseases is resulting in increased consumption of therapeutic drugs and therapies, and this factor is expected to act as a driver for the growth of the drug delivery devices market. The regulatory changes related to medical devices is expected to restrain the growth of the drug delivery devices market. The companies operating in the market are required to adapt according to the changes in the regulatory framework, which may limit business at the bottom line. Also, companies will have to bear the heavy cost of adapting to the changing regulatory framework. Also, the sudden changes in the regulatory framework related to medical devices can result in losses, fines, and penalties at a global level. The new MDSAP will come into effect in 2020 and is adopted by regulators in the US, Canada, Japan, Brazil, and Australia. Following the changes, in Canada, all the medical device manufacturers including drug delivery products manufacturers, will have to comply with the requirements of MDSAP and are required to submit the MDSAP reports to the regulatory body in order to obtain or maintain the device licenses, resulting in high costs and time loss. Thus, the growth of the drug delivery devices market is limited by the regulatory changes related to medical devices. The microneedle (MN), is a highly efficient and versatile medical device technology, due to its prominent properties including painless penetration, low cost, excellent therapeutic efficacy, and relative safety. The major players operating in the global microneedle drug delivery system include 3M, Vetter Pharma International GmbH, nano Biosciences LLC., Nano Pass and more. The microneedles are fabricated using biodegradable polymers in which drugs or vaccines are encapsulated in the microneedles. Once, the microneedles dissolve in the skin, the drug gets released. This novel delivery method allows a wider variety of molecules to pass the skin’s barrier, thus allowing the transdermal delivery to be applied to a large range of clinical applications, including diabetes, severe osteoporosis, and influenza vaccination. Companies in the drug delivery devices market are collaborating with other companies within the industry in order to strengthen their product portfolio as well as expand their footprint across different geographies. For example, in October 2022, Nemera, a French pharmaceuticals company, partnered with Zollner Elektronik AG to develop electronic drug delivery systems. Zollner would provide its design, development, and manufacturing capabilities to help Nemera develop electronic drug delivery system. In August 2020, Sulzer, a Swiss-based engineering and manufacturing firm acquired Haselmeier GmbH for $118m. The acquisition of Haselmeier will allow Sulzer to complement its healthcare portfolio, in addition to leveraging its APS expertise in precision injection moulding to expand its presence in the drug delivery devices market. Haselmeier GmbH, a Swiss-German drug delivery device developer and manufacturer. Major players in the drug delivery devices market are F. Hoffmann-La Roche Ltd., 3M Company, Pfizer Inc., Baxter International, BD, Novartis AG, Gerresheimer AG, Johnson & Johnson Services, Inc., Bayer AG, and GlaxoSmithKline PLC. North America was the largest region in the drug delivery devices market in 2022. Asia-Pacific was the second-largest region in the global drug delivery devices market. The regions covered in the global drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The drug delivery devices market consists of sales of instruments such as smart pills, inhalers and nebulizers, drug-eluting stents, safety syringes, and transdermal patches. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global drug delivery devices market is segmented - 1) By Route Of Administration: Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery, Nasal Drug Delivery, Transmucosal Drug Delivery, Implantable Drug Delivery 2) By Patient Care Setting: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Home Care Settings, Other Patient Care Settings 3) By Application: Cancer, Infectious Diseases, Respiratory Diseases, Diabetes, Cardiovascular Diseases, Autoimmune Diseases, Central Nervous System Disorders, Other Applications

Smart pills are used to deliver medication and are equipped with electronic sensors that emit signals to be captured by patches or smartphones when they are swallowed. These pills ensure drug regimen compliance and help track medication adherence of patients. The main applications of smart pills are capsule endoscopy, patient monitoring, and drug delivery, patient monitoring involves the repeated or continuous observations or measurements of the patient parameters. These pills are used to target the esophagus, stomach, small intestine, and large intestine to treat diseases such as esophageal diseases, colon diseases, small bowel diseases, and others. Smart pills are used by various end-users such as hospitals, diagnostic centres, and research institutes. The smart pills market research report is one of a series of new reports from The Business Research Company that provides smart pills market statistics, including smart pills industry global market size, regional shares, competitors with a smart pills market share, detailed smart pills market segments, market trends and opportunities, and any further data you may need to thrive in the smart pills industry. This smart pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global smart pills market size will grow from $4.48 billion in 2022 to $4.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global smart pills market size is expected to grow to $7.61 billion in 2027 at a CAGR of 11.2%. The growing preference for non-invasive procedures is driving the smart pills market. The non-invasive procedures are diagnostic and treatment procedures that do not require an incision on the body or removal of tissues for the treatment or diagnosis. Smart pill is a wireless, ingestible capsule that can be easily swallowed and has a wide range of applications in capsule endoscopy, drug delivery, and patient monitoring. For instance, smart pills have key applications in diagnostic imaging such as capsule endoscopy. The capsule endoscopy is a diagnostic procedure in which a smart pill (capsule enclosed micro-camera) is swallowed and images of the esophagus, stomach, and small intestine can be taken as the device pass through your gastrointestinal (GI) tract. Smart pills have revolutionized the diagnosis of gastrointestinal disorders and could replace conventional diagnostic techniques such as endoscopy. Therefore, non-invasive procedures are driving the smart pills market during the period. The high cost of smart pills associated with technological advancement will act as a restraint to the market growth. The utilization of advanced technologies including software up-gradation and innovative systems, and the integration of microchips contribute to the high manufacturing costs of the smart pills. Smart pills are a combination of drug and device technology. A smart pill is an innovative method of drug delivery, which involves the use of sensors and cameras embedded into tiny edible devices. Such medical devices ensure better diagnostics, monitoring, and treatment of life-threatening medical conditions by allowing doctors to monitor their patients’ body functions in real-time. However, the high cost of smart pills led to the limited utilization of products in underdeveloped countries. Thus, the high cost is considered as one of the factors that restrain the growth of the small pills market. Extensive research and development are being carried out on the use of miniature chips such as Addressable Transmitters Operated as Magnetic Spins (ATOMS) which can be used as smart pills. ATOMS are silicon chip devices that use the principle of magnetic resonance imaging (MRI) to determine the location of atoms in a patient’s body using magnetic fields. ATOMS can be used in ingestible smart pills to diagnose and treat diseases from within the body. The devices can be used to monitor a patient’s gastrointestinal tract, blood, or brain. They also could measure factors that indicate the health of a patient such as pH, temperature, pressure, and sugar concentrations, and relay that information to doctors. The devices could even be instructed to release drugs. For instance, scientists at Caltech (California Institute of Technology) have developed a miniature medical chip that can be used as a smart pill. Major players in the smart pills market are Medtronic PLC., Olympus Medical Technology, CapsoVision, Inc., Novartis AG, Proteus Pharmaceuticals, Philips Healthcare, Microchips, Bio-Images Drug Delivery (BDD) Limited, Given Imaging, Inc., and Vitality. North America was the largest region in the smart pills market in 2022. Western Europe was the second-largest region in the global smart pills market. The regions covered in the global smart pills market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the smart pills market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The smart pills market consists of sales of instruments that are used in applications such as capsule endoscopy, drug delivery, and patient monitoring. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global smart pills market is segmented - 1) By Application: Capsule Endoscopy, Patient Monitoring, Drug Delivery 2) By End User: Hospital, Diagnostic Center, Research Institute 3) By Target Area: Esophagus, Stomach, Small Intestine, Large Intestine 4) By Disease Indication: Esophageal Diseases, Colon Diseases, Small bowel Diseases, and Other Disease Indications

Oral contraceptive pills refer to a contraceptive tablet that contains hormones that prevent the release of eggs from the ovaries. Oral contraceptives typically contain progestin and oestrogen. Also known as the "birth control pill," it comprises hormones that prevent the emergence of eggs from the ovaries. Most oral contraceptives involve estrogen and progestin.   The oral contraceptive pills market by type into the combination, progestin-only, others; by category into generic, branded; by distribution channel into hospital pharmacy, retail pharmacy, clinics, online channel, public channel and NGO, others. The oral contraceptive pills market research report is one of a series of new reports from The Business Research Company that provides oral contraceptive pills market statistics, including oral contraceptive pills industry global market size, regional shares, competitors with an oral contraceptive pills market share, detailed oral contraceptive pills market segments, market trends and opportunities, and any further data you may need to thrive in the oral contraceptive pills industry. This oral contraceptive pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global oral contraceptive pills market grew from $20.13 billion in 2022 to $21.61 billion in 2023 at a compound annual growth rate (CAGR) of 7.35%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The oral contraceptive pills market size is expected to grow to $36.09 billion in 2027 at a CAGR of 13.68%. The high incidence of unintended pregnancies is expected to drive the growth of the oral contraceptive pills market over the coming years. Unintended pregnancy is a pregnancy that is always unwanted, such as a pregnancy where no children have been planned. The University of California, San Francisco (UCSF) study shows that the rates of unwanted pregnancy and abortion declined substantially when women received a one-year prescription of oral contraceptives. According to the World Health Organization (WHO), 74 million women living in low-middle-income economies register unplanned pregnancies every year globally. The WHO’s research noticed that 4,794 women had unplanned pregnancies after they had discontinued using contraceptives. Therefore, the need to avoid unintended pregnancies drives the growth of the oral contraceptive pills market. The side effects associated with the use of contraceptive drugs are expected to hinder the growth of the oral contraceptive pills market over the forecast period. An oral contraceptive pill is a hormonal procedure to avoid childbirth. The side effects vary between people and the type of pill consumed. Breast tenderness, headaches, spotting, and nausea are some prominent side effects of oral contraceptive pills. Depo-Provera, an implantable contraceptive, is known to provide the most severe side effects. Research has indicated that Depo-Provera and Depo-SubQ Provera 104 can trigger bone mineral density loss. The U.S. Food and Drug Administration (FDA) attached strict notices to the injection kit saying Depo-Provera and Depo-SubQ Provera 104 could not be used for more than 2 years, attributing to their side effects. The notice also suggests that the use of these medications may increase the risk of osteoporosis and bone disorders later in life. Hence, the side effects associated with the use of contraceptive drugs hamper the growth of the oral contraceptive pill market. Major institutes and companies operating in the oral contraceptive pill sector are focusing on developing innovative solutions for oral contraceptive pills. For instance, in July 2022, HRA Pharma, a France based innovative healthcare company, developed an over the-counter birth control pill called "Opill." HRA Pharma has submitted an application to the Food and Drug Administration in the United States. Opil is a progestin-based contraceptive that helps people access contraception without facing any difficulty. In January 2020, Theramex, a speciality pharmaceutical company for women announced the acquisition of rights to Zoely®, a patented oral contraceptive from Merck &Co for an undisclosed amount. This acquisition aids Theramex in global expansion and adding innovative treatment options for women to its portfolio. Merck & Co. is a US-based multinational pharmaceutical company that has oral contraceptives in its product portfolio. Major players in the contraceptive pills market are Teva Pharmaceutical Industries Ltd., Bayer AG, Syzygy Healthcare, Mankind Pharma Ltd., Pfizer Inc., Piramal Enterprises Ltd., Ferring B.V, Merck & Co. Inc., Johnson & Johnson, and Lupin Pharmaceuticals Inc. North America was the largest region in the oral contraceptive pills market in 2022. The Middle East is expected to be the largest growing region in the forecast period. The regions covered in the contraceptive pills market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the contraceptive pills market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The oral contraceptive pills market consists of sales of combined estrogen-progesterone, progesterone-only, and continuous or extended use pill. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global oral contraceptive pills market is segmented - 1) By Type: Combination, Progestin Only, Other Types 2) By Category: Generic, Branded 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel And NGO, Other Distribution Channels

Implantable drug delivery devices are drug delivery systems implanted under the skin that transmit drugs into the bloodstream from a reservoir. These devices facilitate site specific drug delivery and require smaller doses, thereby minimising side effects. The main products of implantable drug delivery devices is contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bioabsorbable stents, intraocular stents, infusion pumps, and others. Spinal implants are devices that are used by surgeons while performing surgery to treat deformity, stabilise and strengthen the spine, and facilitate fusion. The technologies involved are diffusion, osmosis, magnetic, and others. The various applications involved are contraception, ophthalmology, cardiovascular, diabetes, oncology, autoimmune diseases, and others. The implantable drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides implantable drug delivery devices market statistics, including implantable drug delivery devices industry global market size, regional shares, competitors with a implantable drug delivery devices market share, detailed implantable drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the implantable drug delivery devices industry. This implantable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global implantable drug delivery devices market grew from $18.35 billion in 2022 to $19.58 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The implantable drug delivery devices market is expected to grow from $26 billion in 2027 at a CAGR of 7.3%. The rise in the incidence of target diseases such as diabetic retinopathy, cancer, cardiovascular diseases, and other chronic diseases is expected to drive the implantable drug delivery devices market. According to the International Diabetes Federation (IDF), the global prevalence of diabetic retinopathy was one in three in 2020. Implantable drug delivery devices are used for site-specific drug administration where the drug is most needed, such as Gliadel® wafer as an implant used in the treatment of brain tumors, Lupron depot for the treatment of prostate cancer. Hence, the site-specific drug administration nature of implantable drug devices, which help in the treatment of target diseases, is driving the implantable drug delivery devices market. The rising number of product recalls and lawsuits associated with implantable drug delivery devices is expected to hinder the market. In the past few years, there had been an increase in product recalls and lawsuits connected with these devices. For instance, in June 2022, Medtronic plc recalled Cobalt XT, Cobalt, and Crome Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) for the reasons of reports of devices with a short circuit protection (SCP) alert resulting in reduced-energy electric shock delivery, instead of delivering a second phase of high voltage therapy. This may result in failure of device and irregular heartbeat which can lead to more serious issues. Therefore, the rising number of product recalls and lawsuits concerning implantable drug delivery devices is expected to hinder the growth of the market. Companies and researchers are focusing on developing 3D implantable drug delivery devices. 3D printed titanium transcutaneous ports are implanted behind the patient's ear, allowing healthcare professionals to access the catheters. For instance, in February 2020, Renishaw and Herantis Pharma announced the award-winning device, which received positive results in phase 2 trials, that consists of up to four catheters implanted in the relevant brain areas. Researchers at King Abdullah University of Science and Technology have introduced a miniaturized drug delivery system suitable for in-vivo biomedical applications. The system consists of an electrolytic pump, which operates a micro bellows membrane as an actuator for delivery through microneedles. A two-photon 3D printing technique was used to make a reservoir equipped with a microneedle. In February 2022, Second Sight Medical Products, a California-based manufacturer of prosthetic devices, merged with Nano Precision Medical. The companies would collaborate to develop drug delivery medical implants.Nano Precision Medical is a US-based developer of NanoPortal drug implant technology. Major players in the implantable drug delivery devices market are Allergan Inc., Bayer HealthCare, Medtronic Inc., Nucletron, Boston Scientific Corporation, Abbott Laboratories, Bausch and Lomb Inc., Merck, Genetech Inc., and Psivida. North America was the largest region in the implantable drug delivery devices market in 2022. Asia-Pacific was the second-largest region in the global implantable drug delivery devices market report. The regions covered in the global implantable drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the implantable drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The implantable drug delivery devices market consists of sales of contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bio-absorbable stents, intraocular stents, infusion pumps, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global implantable drug delivery devices market is segmented - 1) By Product: Contraceptive Implants, Spinal Implants, Brachytherapy Seeds, Drug-Eluting Stents, Bio-absorbable Stents, Intraocular Stents, Infusion Pumps, Other Applications 2) By Technology: Diffusion, Osmotic, Magnetic, Other Technologies 3) By Application: Contraception, Ophthalmology, Cardiovascular, Diabetes, Oncology, Autoimmune Diseases, Other Applications

Injectable drug delivery devices are used for various routes of drug administration such as intravenous, subcutaneous, intradermal, intra-peritoneal, and intra-muscular. The main types of injectable drug delivery devices are conventional injectable, pre-filled syringes, auto-injectors, and pen-injectors. The prefilled syringes are the packaging with the fixed needle that contains single-dose vaccines or other medications. The injectable drug delivery devices offer applications such as autoimmune diseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, and others that are used by various end-users such as hospitals and clinics, home healthcare settings, pharmaceutical and biotechnological companies, research laboratories, and others. The injectable drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides injectable drug delivery devices market statistics, including injectable drug delivery devices industry global market size, regional shares, competitors with a injectable drug delivery devices market share, detailed injectable drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the injectable drug delivery devices industry. This injectable drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global injectable drug delivery devices market size will grow from $39.93 billion in 2022 to $43.54 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global injectable drug delivery devices market size is expected to grow from $58.1 billion in 2027 at a CAGR of 7.5%. The increasing preference for self-injection devices is driving the injectable drug delivery devices market. Self-injection devices are medical devices that can be used by the patient in-home setting for self-administration of the medication. Self-injection devices include needle-free, auto, pen, and wearable injectors. These self-injectables were developed to provide the most adaptable device which has a high precision of drug delivery and is easy to use. In addition, with the innovations in self-injectable devices, the acceptance of these products has increased over the past few years. BD Physioject is a disposable auto-injector, manufactured by Becton, Dickinson, and Company, which is clinically proven, reliable, and cost-effective specifically designed for self-injection of drugs by patients suffering from chronic diseases, including rheumatoid arthritis, multiple sclerosis, asthma, and osteoporosis. The other companies currently involved in the self-injections market include Abbvie, Inc., 3M, Baxter, Gerresheimer AG, Pfizer Inc., and more. The advantages of self-injectable injections and increasing awareness of self-administration have increased the demand for self-injectable devices and will drive the injectable drug delivery devices market during the forecast period. The emergence of alternative drug delivery devices to injectable drug delivery devices is negatively affecting the market. Injectable (parenteral) drug delivery is one of the widely used conventional drug delivery systems. There are many alternative (painless) drug delivery systems such as nasal, transdermal, transmucosal, vaginal, anal, and others that are evolving. The selection of a drug delivery system depends on the drug release, absorption, distribution, metabolism, and elimination profile of the therapeutic agent to achieve the highest level of safety and efficacy from the drug. Alternative drug delivery systems hold key importance in improving bioavailability, reducing toxicity, and safety elimination of drug which is administered to treat a particular disease. Growing disease-related complications, regular developments in drugs, and combinations of therapeutic agents are used to treat disease driving the need for alternative drug delivery systems. There are some recent ongoing developments in the field of alternative drug delivery systems mainly in a nanoparticles-based delivery system, intracellular delivery system, neural delivery system, and many more. Thus, the emergence of alternative drug delivery methods limits the growth of the injectable drug delivery devices market. The companies in injectable drug delivery devices are increasingly focusing on the manufacturing of auto-injectors. The auto-injectors are fully automated, highly customized, and reusable injectors that can be used by a patient to perform hundreds of injections. Patients can control the speed of dose delivery to help minimize pain or discomfort during injection. These devices can adjust the speed and depth of the automatic injection. For instance, LISA, a reusable auto-injector manufactured by Unilife corporation comes with an array of highly customizable features including Bluetooth LE connectivity, Wi-Fi or 3G connectivity, and pre-injection drug warming for target therapies. The injectable drug delivery technology market is expected to show significant growth in the coming years, due to various technological advancements and new product launches to improve the convenience and ease of administration of parenteral therapeutics. Major players in the injectable drug delivery devices market are Becton, Dickinson and Company, Gerresheimer AG, Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Schott AG, Baxter International, Owen Mumford, Mylan N.V., and Sanofi. North America was the largest region in the injectable drug delivery devices market in 2022. Western Europe was the second-largest region in the global injectable drug delivery devices market. The regions in the global injectable drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries included in the injectable drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The injectable drug delivery devices market consists of sales of conventional syringes, needle-free injectors, auto-injectors, and pen injectors. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global injectable drug delivery devices market is segmented - 1) By Type: Conventional Injectable, Pre-filled Syringes, Auto-injectors, Pen-injectors 2) By Application: Autoimmune Diseases, Hormonal Disorders, Oncology, Orphan Diseases, Pain Management, Respiratory Therapy, Other Applications 3) By End User: Hospitals And Clinics, Home Healthcare Settings, Pharmaceutical And Biotechnological Companies, Research Laboratories, Other End Users

A microneedle drug delivery system is a device with hundreds of microneedles on a patch that delivers a sufficient amount of drug in treatment. The main types of technologies in microneedle drug delivery systems are solid microneedle technology, hollow microneedle technology, dissolved microneedle technology, and others. Peptides are dried on the tips of a microneedles array in the solid microneedles method, which uses a coating of powerful chemicals. The solid microneedles are 250 micrometers to 700 micrometers in length and come in patch form that can be stored at room temperature. The microneedle drug delivery systems are used for drug delivery, vaccine delivery, others and employed in diagnostic laboratories, life sciences, research laboratories, hospitals, ambulatory surgical centers, and others. The microneedles drug delivery systems market research report is one of a series of new reports from The Business Research Company that provides microneedles drug delivery systems market statistics, including microneedles drug delivery systems industry global market size, regional shares, competitors with a microneedles drug delivery systems market share, detailed microneedles drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the microneedles drug delivery systems industry. This microneedles drug delivery systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global microneedle drug delivery systems market size grew from $3.62 billion in 2022 to $4.07 billion in 2023 at a compound annual growth rate (CAGR) of 12.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The microneedle drug delivery systems market size is expected to grow to $7.84 billion in 2027 at a CAGR of 17.8%. The increase in research and demand for the vaccination process are predicted to drive the microneedle drug delivery systems market growth. Researchers view microneedle as an alternative way to inject vaccines where the receiver of the vaccine is expected to not feel any sensation of pain. Microneedle patches vaccine was developed initially for flu and measles; however, the technology is now being used increasingly for delivery of COVID-19 vaccine as well. For instance, in 2020, The University of Connecticut, Vaxess, and Verndari are using microneedles to deliver viral proteins into the skin, where they induce an immune response. According to a Bloomberg report, more than 3.98 billion doses of vaccine have been administered across 180 countries until July 2021. Increased demand from government and health research and development bodies for microneedle drug delivery technology propels the market for microneedle drug delivery systems going forward. Biodegradable microneedles drug delivery patches are increasingly used in local therapeutic gene delivery and treatment of chronic diseases. The use of biodegradable microneedles patches helps in easy and fast delivery of genes through targeting the skin as a site for local delivery. Gene delivery and treatment with these patches are easily accessible and contain fluid and lymph vessels that help the genetic material to act effectively. For instance, in 2020, a group from Terasaki Institute for Biomedical Innovation has recently worked on optimizing the release and performance of the biodegradable patches. Biodegradable microneedles patches offer several advantages in gene delivery such as improved efficacy, fast delivery, customized delivery, and others. In May 2020, Altaris Capital Partners, a US-based company acquired Kindeva Drug Delivery for $650 million. The deal is expected to help Altaris to develop and provide more innovative drug delivery technologies to the healthcare system by using the expertise of 3M and the Kindeva team. Kindeva Drug Delivery (Formerly known as 3M Drug Delivery Systems) is an American manufacturer of pharmaceutical and biotechnology products including inhalation, microneedle, and transdermal drug delivery technologies used for the treatment of cardio and respiratory health conditions. Major players in the microneedle drug delivery systems market are 3M, Zosano Pharma, Becton-Dickinson Technologies, Nanopass Technologies, Corium, Valeritas, Microdermics, TheraJect Inc., LTS Lohmann Therapie-Systeme AG, BioSerenTach (BT), Sorrento Therapeutics, Debiotech, Raphas Co. Ltd., QuadMedicine, SNvia, and NanoBiosciences. North America was the largest region in the microneedles drug delivery systems market in 2022. Europe was the second-largest region in the microneedles drug delivery systems market. The regions covered in the microneedles drug delivery systems report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the microneedle drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The microneedles drug delivery systems market consists of sales of hydrogel microneedles and dissolvable microneedle. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global microneedle drug delivery systems market is segmented - 1) By Technology: Hollow, Porous, Solid, Other Technologies 2) By Application: Drug Delivery, Vaccine Delivery, Other Applications 3) By End-User: Diagnostics Laboratories, Life Sciences, Research Laboratories, Hospitals, Ambulatory Surgical Centers, Other End-Users